they dont even know dosing strategies that will work etc.
you must be joking rev monster.... no dosing strategies?? They just doubled MOS in the phase II and the Bavi+Doce arm in Sunrise was "GOING AS EXPECTED" with no problems in the Bavi arm...
When you have a platform with hardly no side effects.... dosing becomes less and less of an issue.
I wonder what dosing strategy NCCN will come up with
You seem to forget about those studies going on ??? : )
"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical pipeline." -- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!